Regional but fatal: Intraperitoneal metastasis in gastric cancer

Wei, Jia; Wu, Nan; Liu, Baorui

doi:10.3748/wjg.v22.i33.7478

Cited by 56 publications

(44 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gastric cancer, one of the most common malignant tumors worldwide [1], arises from the gastric mucosal epithelium and severely affects patient health and quality of life. There are obvious regional differences in its occurrence, with Japan, Korea, and China being the areas with the highest risk in Asia [1,2]. In particular, gastric cancer is one of the most prominent malignant tumors in China [3].…”

Section: Introductionmentioning

confidence: 99%

Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin

Ren

Zhang

2020

BioMed Research International

View full text Add to dashboard Cite

Objective. Gastric cancer, one of the most common malignant tumors worldwide, arises from the gastric mucosal epithelium and severely affects patient health and quality of life. Luteolin (LUT) is a flavonoid found in vegetables and fruits with diverse functions. A large number of studies have confirmed that LUT has an antitumor effect. Therefore, this study is aimed at verifying whether LUT can exert antitumor effects in synergy with oxaliplatin (OXA). As such, we examined the effects of LUT, OXA, and their coadministration in a gastric adenocarcinoma cell line (SGC-7901). We used the MTT assay to quantify the proliferation of SGC-7901 cells, flow cytometry to detect the cell cycle and apoptosis, ELISA to detect the expression of cell-cycle-related proteins, and western blot to detect the expression of related apoptotic factors. The results of this study show that the combination of LUT and OXA inhibited SGC-7901 cell proliferation and induced apoptosis by altering cell-cycle proportions. In addition, the combination also activated Cyt c/caspase signaling in SGC-7901 cells. In summary, LUT synergy with OXA inhibited the proliferation of gastric cancer cells in vitro. The present study also elucidated the mechanism by which LUT potentiated the sensitivity of SGC-7901 cells to OXA through the Cyt c/caspase pathway.

show abstract

Section: Introductionmentioning

confidence: 99%

Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin

Ren

Zhang

2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…It is common that most patients were diagnosed in advanced stage of GC only. And many patients are suffering from the metastatic recurrences even after curative resection [ 3 ]. Although several improvements have been achieved in the surgical treatment of gastric cancer, the overall 5-year survival rate for all diagnosed patients is only 24.5 % in Europe [ 4 ] and 40 %-60 % in Asia [ 5 , 6 ], resulting from high recurrence rate.…”

Section: Introductionmentioning

confidence: 99%

Identification and validation of a prognostic 9-genes expression signature for gastric cancer

et al. 2017

View full text Add to dashboard Cite

Gastric cancer (GC) is a common malignant tumor with high incidence and mortality. Reasonable assessment of prognosis is essential to improve the outcomes of patients. In this study, we constructed and validated a prognostic gene model to evaluate the risks of GC patients. To identify the differentially expressed genes between GC patients and controls, we extracted Gene expression profiles of GC patients (N=432) from Gene Expression Omnibus database and then stable signature genes by using Robust likelihood-based modeling with 1000 iterations. Unsupervised hierarchical clustering of all samples was performed basing on the characteristics of gene expressions. Meanwhile, the differences between the clusters were analyzed by Kaplan Meier survival analysis. A 9-genes model was obtained (frequency = 999; p=1.333628e-18), including two negative impact factors (NR1I2 and LGALSL) and 7 positive ones (C1ORF198, CST2, LAMP5, FOXS1, CES1P1, MMP7 and COL8A1). This model was verified in single factor survival analysis (p=0.004447558) and significant analysis with recurrence time (p=0.001474831) by using independent datasets from TCGA. The constructed 9-genes model was stable and effective, which might serve as prognostic signature to predict the survival of GC patients and monitor the long-term treatment of GC.

show abstract

“…Serozal tutulunumun bir diğer sonucuda tümör hücrelerinin dökülerek peritoneal karsinomatoza öncülük etmesidir (15). Yapılan araştırmalarda mide kanserinin solid organ metastazları ve buna bağlı gelişen mortaliye oranı %40'larda iken daha erken mortalite ile giden peritoneal karsinomatozisin eşlik ettiği durumda ise bu oran %60'lardadır (16,17).…”

Section: Discussionunclassified

Cytoreductive Surgery and Hyperthermic İntraperitoneal Chemoterapy for Advance Gastric Cancer Associated Peritoneal Carcinomatosis Single Centre Unit for 10 Consecutive Patients

Düzgün¹,

Yuksekdag²,

Kalın³

et al. 2019

Haseki

View full text Add to dashboard Cite

Sitoredüktif cerrahi ile beraber hipertermik intraperitoneal kemoterapi uygulamasının ileri evre abdominal kanserlerde sağ kalıma olumlu etkisi olduğu gösterilmiştir. Bu konuda özellikle son iki dekatta mide kanseriyle de alakalı güncel bilgiler mevcut olup bu çalışmada peritoneal karsinomatozun eşlik ettiği mide kanser olgularında sitoredüktif cerrahi ve hipertermik intraperitoneal kemoterapi deneyimimizi literatür eşliğinde sunmayı amaçladık. Yöntemler: Haziran 2017-Kasım 2018 tarihleri arasında mide kanseri tanısı almış, yapılan tetkiklerinde peritoneal karsinomatozisin eşlik ettiği hastalar çalışmaya dahil edildi. Prospektif olarak toplanan verilerin değerlendirilmesi ile hastaların demografik verileri, kısa dönem takip sonuçları,ameliyat bulguları,peritoneal karsinomatozis indeks skoru, rezeksiyon tamlık skoru ,morbidite ve mortalite oranları analiz edildi. Bulgular: Mide kanseri zemininde peritoneal karsinomatozis gelişen 10 olgu çalışmaya dahil edilmiş olup hastaların yaş ortalaması 60,3 idi. Cinsiyet açısından bakıldığında, yedisi erkek üçü kadındı. Hastaların ortalama takip süresi 6 ay olup en az 1 en çok 15 aydı. Postoperatif bir olguda anastomoz kaçağı gelişti. Diğer dokuz olguda mortaliteye neden olacak herhangi bir morbidite gelişmedi. Aim: Hyperthermic intraperitoneal chemotherapy with cytoreductive surgery has a positive effect on survival in advanced abdominal cancers. We aimed to present our experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer patients with peritoneal carcinomatosis and a review of the literature. Methods: Ten patients (seven male, three female) who were diagnosed with gastric cancer between June 2017 and November 2018 were included in the study. Data on demographic characteristics, short-term follow-up results, surgical findings, peritoneal carcinomatosis index score, completeness of cytoreduction score, and morbidity and mortality rates were retrospectively analyzed. Results: The mean age of the patients was 60.3 years. The mean follow-up period was six months (1-15 months). One patient developed an anastomotic leak. In the other nine cases, there was no morbidity leading to mortality. Conclusion: While gastric cancer with peritoneal carcinomatos has a poor survival, less than six months with non-operative approach, treatment with cytoreductive surgery and hyperthermic

show abstract

Regional but fatal: Intraperitoneal metastasis in gastric cancer

Cited by 56 publications

References 70 publications

Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin

Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin

Identification and validation of a prognostic 9-genes expression signature for gastric cancer

Cytoreductive Surgery and Hyperthermic İntraperitoneal Chemoterapy for Advance Gastric Cancer Associated Peritoneal Carcinomatosis Single Centre Unit for 10 Consecutive Patients

Contact Info

Product

Resources

About